BLFS
BioLife Solutions Inc
38.50$
-0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 75.7% | 56.4% | 58.4% | 81.8% | 82.6% | 26.0% | 48.8% | 22.7% | 30.8% | 29.2% | 37.2% | 33.6% | |
| 15.8% | 30.9% | 17.7% | 54.9% | 67.4% | 6.9% | 38.5% | 12.6% | 4.3% | 6.8% | 23.9% | 8.1% | |
| 61.8% | 30.9% | 17.7% | 54.9% | 67.4% | 6.9% | 38.5% | 12.6% | 13.9% | 10.7% | 26.2% | 21.9% | |
| 5.6% | 7.5% | 15.1% | 8.4% | 6.7% | 5.7% | 3.4% | 4.2% | 7.5% | 4.5% | 2.3% | 2.0% | |
| 6.0% | 14.8% | 22.2% | 15.2% | 7.7% | 12.0% | 4.9% | 5.1% | 7.8% | 10.5% | 7.3% | 7.4% | |
| 10.3% | 25.4% | 15.0% | 9.1% | 2.9% | 6.0% | 10.4% | 8.4% | – | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | – | 36.2% | 24.9% | 40.5% | 49.9% | 54.5% | 53.1% | 51.4% | |
| 13.8% | 31.6% | 49.4% | 0.0% | – | 23.6% | 13.2% | 27.4% | 7.1% | 5.1% | 2.4% | 1.0% | |
| 13.3% | 20.3% | 60.1% | 16.9% | 67.8% | 53.1% | 12.6% | 13.8% | 19.1% | 18.2% | 12.7% | 8.4% | |
| 7.9% | 14.0% | 14.3% | 12.5% | 4.3% | 8.2% | 6.6% | 7.7% | 9.9% | 10.2% | 8.2% | 5.7% | |
| – | – | 35.9% | – | – | 0.9% | 0.7% | 0.7% | 1.1% | 1.8% | 3.1% | 1.8% | |
| 3.0% | 8.3% | 9.0% | 5.7% | 1.6% | 3.4% | 1.6% | 2.7% | 3.4% | 1.7% | 0.9% | 0.4% | |
| – | 0.0% | 35.9% | 0.0% | – | – | 0.3% | 1.1% | 5.3% | 4.4% | 1.3% | – | |
| 73.4% | 68.8% | 39.9% | 83.1% | 32.2% | 89.3% | 87.4% | 86.2% | 80.9% | 81.8% | 87.3% | 91.6% | |
| -374.0% | -520.0% | -898.2% | -609.1% | -216.4% | -107.6% | -41.5% | -19.3% | -54.8% | -75.9% | -83.9% | -83.7% | |
| 65.0% | 98.4% | 159.5% | 109.2% | 35.8% | 20.9% | 11.6% | 6.9% | 9.4% | 10.6% | 11.5% | 12.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.